The dual biomarker assays market is projected to rise from USD 1.4 billion in 2025 to USD 4.3 billion by 2035, reflecting a CAGR of 11.7% during the forecast period. Cancer indications dominate the industry with an 87% share in 2025, while Immunochemistry assays lead the assay type segment with a 60% share.